Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bio-Rad debuts anti-cemiplimab antibodies

By Brian Buntz | April 11, 2022

Bio-RadBio-Rad Laboratories, Inc. (NYSE:BIO) has launched a line of antibodies specific to cemiplimab (Libtayo).

The antibodies inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).

Hercules, California–based Bio-Rad Lab, said the ready-made antibodies could be used to develop selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab.

Cemiplimab, developed by Regeneron and Sanofi-Aventis U.S., acts as a checkpoint inhibitor by binding to PD-1 on T cells.

It blocks the interaction with its ligands, PD-L1 and PD-L2, to activate T cells to attack cancer cells.

Bio-Rad reports that the anti-cemiplimab antibodies with varying degrees of affinity provide flexibility for bioanalytical ligand binding assays.

“These critical antibody reagents support researchers developing bioanalytical assays for checkpoint inhibitor drugs by providing sequence-defined, well-characterized reagents with stable supply,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group, in a press release. “The introduction of TrailBlazer Antibodies to the range brings added flexibility for bioanalytical assay design,” she said.

 


Filed Under: Biospecimens
Tagged With: Bio-Rad, cemiplimab, human programmed death receptor-1, Libtayo, PD-1
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

NBC 2025 Preview: Inside CheckImmune’s playbook for cell-specific drug insights
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
Prime time for peptide-based drug discovery 
Spatial biology: Transforming our understanding of cellular environments
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE